| GOG-0240 | A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities: Chemotherapy: Systemic Immunotherapy
| Randomized: Yes Principal Investigator(s): Huyen Q. Pham Staff Members: Kristy Watkins Grace Facio Marissa Aldana Yvonne Flores
|